Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regina Paleski

Set Alert for Articles By Regina Paleski

Latest From Regina Paleski

Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine

Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.

Appointments BioPharmaceutical

Execs On The Move, January 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Companies

Executives On The Move: BD Moves From Roche And BMS To Compugen And Turnstone

A Roche director joins predictive drug discovery firm Compugen and a Bristol-Myers Squibb exec is welcomed at immuno-oncology company Turnstone Biologics – both in Business Development. And China- and US-based biopharma Antegene brings on Celgene manager as CBO.


Executives On The Move: Departures At Ipsen And Novo Nordisk And A Board Change At PDL BioPharma

The CEO of Ipsen Group departs to take top job at new gene therapy company FerGene and Novo Nordisk’s VP, regulatory affairs moves to EVP, quality and regulatory at Scandinavian orthobiologics firm BoneSupport. At commercial-stage pharma business PDL BioPharma, a chairperson is elected.

Appointments BioPharmaceutical

Executives On The Move: Five New CEOs Announced

New CEOs for Abgenomics, Advangen, Dynavax Technologies, Merus and Nuvelution are among the latest biopharma appointments. Kiadis Pharma’s CFO’s resignation takes effect on 31 December.

Appointments BioPharmaceutical

Executives On The Move: Operations Change At Khondrion And A Promotion At Grunenthal

Khondrion BV, developer of therapies for mitochondrial disease, has appointed a former Novartis SVP as COO, and pain and inflammation medicines firm Grunenthal GmbH to promote acting CSO to CSO and director. Also, Royal DSM NV says CEO to resign in February.

Appointments BioPharmaceutical
See All